Sera from donor animals are used to protect acutely sick patients from dangerous diseases (e.g. botulism toxin) or to prevent the body from rejecting an organ transplant. The appropriate serum is produced by immunising the donor animals against the specific antigen first, to ensure that there is an appropriate amount of antibody in the blood.
| Name | Description | Marketing Authorisation Holder | License Number | License Date | Use | Further Information |
|---|---|---|---|---|---|---|
Atgam |
Anti-Human-T-Lymphozyten-Immunglobulin vom Pferd |
Pfizer Pharma GmbH |
PEI.H.12030.01.1 | 28.01.2022 | Pferd | |
|
Grafalon |
Anti-Human-T-Lymphozyten-Immunglobulin vom Kaninchen |
Neovii Biotech GmbH |
452a/87 | 08.02.1988 | Kaninchen | |
|
Thymoglobuline |
Anti-Human-T-Lymphozyten-Immunglobulin vom Kaninchen |
Sanofi B.V. |
191a/92 | 04.08.1994 | Kaninchen |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 527 in BAnz AT 12.03.2025 B3.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 14.03.2025
